First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

被引：0

作者：

Baas, P. ^{[1
,2
]}

Scherpereel, A. ^{[3
]}

Nowak, A. ^{[4
]}

Fujimoto, N. ^{[5
]}

Peters, S. ^{[6
]}

Tsao, A. ^{[7
]}

Mansfield, A. ^{[8
]}

Popat, S. ^{[9
]}

Jahan, T. ^{[10
]}

Antonia, S. ^{[11
]}

Oulkhouir, Y. ^{[12
]}

Bautista, Y. ^{[13
]}

Cornelissen, R. ^{[14
]}

Greillier, L. ^{[15
]}

Grossi, F. ^{[16
]}

Kowalski, D. M. ^{[17
]}

Rodriguez-Cid, J. ^{[18
]}

Aanur, P. ^{[19
]}

Baudelet, C. ^{[19
]}

Zalcman, G. ^{[20
]}

机构：

[1] Netherlands Canc Inst, Amsterdam, Netherlands

[2] Leiden Univ, Amsterdam, Netherlands

[3] Univ Lille, CHU Lille, INSERM U1189, Pulm & Thorac Oncol,OncoThAI, Lille, France

[4] Univ Western Australia, Perth, WA, Australia

[5] Okayama Rosai Hosp, Okayama, Japan

[6] Lausanne Univ Hosp, Lausanne, Switzerland

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Mayo Clin, Rochester, MN USA

[9] Royal Marsden Hosp, London, England

[10] USCF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] CHU Caen, Hop Cote De Nacre, Caen, France

[13] Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico

[14] Erasmus MC Canc Inst, Rotterdam, Netherlands

[15] Aix Marseille Univ, Marseille, France

[16] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[17] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[18] Ctr Oncol Med Sur, Mexico City, DF, Mexico

[19] Bristol Myers Squibb Co, Princeton, NJ USA

[20] Univ Paris Diderot, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2908

引用

页码：E42 / E42

页数：1

共 50 条

[1] First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
Scherpereel, Arnaud
Antonia, Scott
Bautista, Yolanda
Grossi, Francesco
Kowalski, Dariusz
Zalcman, Gerard
Nowak, Anna K.
Fujimoto, Nobukazu
Peters, Solange
Tsao, Anne S.
Mansfield, Aaron S.
Popat, Sanjay
Sun, Xiaowu
Lawrance, Rachael
Zhang, Xiaoqing
Daumont, Melinda J.
Bennett, Bryan
McKenna, Mike
Baas, Paul
LUNG CANCER, 2022, 167 : 8 - 16
[2] First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Peters, S.
Scherpereel, A.
Cornelissen, R.
Oulkhouir, Y.
Greillier, L.
Kaplan, M. A.
Talbot, T.
Monnet, I
Hiret, S.
Baas, P.
Nowak, A. K.
Fujimoto, N.
Tsao, A. S.
Mansfield, A. S.
Popat, S.
Zhang, X.
Hu, N.
Balli, D.
Spires, T.
Zalcman, G.
ANNALS OF ONCOLOGY, 2022, 33 (05) : 488 - 499
[3] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Baas, Paul
Scherpereel, Arnaud
Nowak, Anna K.
Fujimoto, Nobukazu
Peters, Solange
Tsao, Anne S.
Mansfield, Aaron S.
Popat, Sanjay
Jahan, Thierry
Antonia, Scott
Oulkhouir, Youssef
Bautista, Yolanda
Cornelissen, Robin
Greillier, Laurent
Grossi, Francesco
Kowalski, Dariusz
Rodriguez-Cid, Jeronimo
Aanur, Praveen
Oukessou, Abderrahim
Baudelet, Christine
Zalcman, Gerard
LANCET, 2021, 397 (10272): : 375 - 386
[4] New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
Laune, Quentin
Brosseau, Solenn
BULLETIN DU CANCER, 2022, 109 (01) : 4 - 6
[5] First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
Peters, S.
Scherpereel, A.
Cornelissen, R.
Oulkhouir, Y.
Greillier, L.
Kaplan, M. A.
Talbot, T.
Monnet, I.
Hiret, S.
Baas, P.
Nowak, A. K.
Fujimoto, N.
Tsao, A. S.
Mansfield, A. S.
Popat, S.
Zhang, X.
Hu, N.
Balli, D.
Sanzari, J.
Zalcman, G.
ANNALS OF ONCOLOGY, 2021, 32 : S1341 - S1342
[6] First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
Zalcman, G.
Oulkhouir, Y.
Cornelissen, R.
Greillier, L.
Cid, J. R. Rodriguez
Mazieres, J.
Briggs, P.
Nowak, A. K.
Tsao, A.
Fujimoto, N.
Peters, S.
Mansfield, A. S.
Popat, S.
Nassar, A.
Bushong, J.
Hu, N.
Spires, T.
Balli, D.
Eccles, L.
Baas, P.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1438 - S1439
[7] Evaluation of flat dosing for nivolumab (NIVO) plus ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)
Tsao, A. S.
Baas, P.
Nowak, A.
Zalcman, G.
Fujimoto, N.
Peters, S.
Baudelet, C.
Aanur, P.
Osawa, M.
Tendolkar, A.
Feng, Y.
Sheng, J.
ANNALS OF ONCOLOGY, 2020, 31 : S1445 - S1445
[8] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Scherpereel, A.
Antonia, S.
Bautista, Y.
Grossi, F.
Kowalski, D.
Zalcman, G.
Nowak, A.
Fujimoto, N.
Peters, S.
Tsao, A.
Mansfield, A.
Popat, S.
Sun, X.
Padilla, B.
Aanur, P.
Daumont, M.
Bennett, B.
McKenna, M.
Baas, P.
ANNALS OF ONCOLOGY, 2020, 31 : S1441 - S1441
[9] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Bischoff, H.
Scherpereel, A.
Antonia, S.
Bautista, Y.
Grossi, F.
Kowalski, D.
Zalcman, G.
Nowak, A.
Fujimoto, N.
Peters, S.
Tsao, A.
Mans-Field, A.
Popat, S.
Sun, X.
Padilla, B.
Aanur, P.
Daumont, M.
Bennett, B.
McKenna, M.
Baas, P.
PNEUMOLOGIE, 2021, 75 : S17 - S17
[10] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
Yang, Liu
Cao, Xueqiong
Li, Na
Zheng, Bin
Liu, Maobai
Cai, Hongfu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14

← 1 2 3 4 5 →